Background: We quantified the expression of various growth-related factors in an adrenocorticotropic hormone (ACTH)-secreting adenoma that had recurred very rapidly as invasive macroadenoma. Methods/Results: A 43-year-old woman underwent successful transsphenoidal surgery for Cushing’s disease. Seven years later, she was admitted to our ward for further endocrine examinations. In spite of a very high plasma ACTH level, the serum cortisol level was normal. Discrepancies between ACTH and cortisol levels were detected on the basis of diurnal rhythms, dexamethasone suppression tests, and corticotropin-releasing hormone test. The patient showed no clinical features of Cushing’s disease. Magnetic resonance imaging of the pituitary showed an almost empty sella, and no microadenoma was found. These results, along with those of Sephadex column gel filtration and high-performance liquid chromatography of plasma-immunoreactive ACTH, suggested that the patient’s residual corticotrophs secreted biologically inactive ACTH. Two years later, the patient suddenly developed diplopia and right abducens nerve palsy. She was slightly moonfaced and centrally obese. Her plasma ACTH and serum and urinary free cortisol levels were elevated, although discrepancies between ACTH and cortisol still existed. Magnetic resonance imaging revealed a large pituitary mass with suprasellar and cavernous sinus extensions. The tumor was excised, and the proopiomelanocortin gene and the expression of growth-related factors were analyzed. No mutations were found in the ACTH-coding region of the proopiomelanocortin gene. A significant expression of insulin-like growth factor II and proliferating cell nuclear antigen mRNAs was demonstrated. A high MIB-1 antibody labeling index was also detected in the adenoma tissue, suggesting high Ki-67 expression. Conclusion: These growth- and proliferation-related factors might be involved in the rapid growth and aggressiveness of this patient’s pituitary adenoma.

Keywords:
Insulin-like growth factor II, Proliferating cell nuclear antigen, MIB-1 antibody, Cushing’s disease, Adrenocorticotropic hormone, Pituitary adenoma
1.
Dahia PLM, Grossman AB: The molecular pathogenesis of corticotroph tumors. Endocr Rev 1999;20:136–155.
2.
Shimon I, Melmed S: Genetic basis of endocrine disease: Pituitary tumor pathogenesis. J Clin Endocrinol Metab 1997;82:1675–1681.
3.
Williamson EA, Ince PG, Harrison D, Kendall-Taylor P, Harris PE: G protein mutations in human pituitary adrenocorticotropic hormone-secreting adenomas. Eur J Clin Invest 1995;25:128–131.
4.
de Keyzer Y, Rene P, Beldjord C, Lenne F, Bertagna X: Overexpression of vasopressin (V3) and corticotrophin-releasing hormone receptor genes in corticotroph tumours. Clin Endocrinol (Oxf) 1998;49:475–482.
5.
Dieterich KD, Gundelfinger ED, Kudecke DK, Lehnert H: Mutation and expression analysis of corticotropin-releasing factor 1 receptor in adrenocorticotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 1998;83:3327–3331.
6.
Korbonits M, Jacobs RA, Aylwin SJP, Burrin JM, Dhaia PLM, Monson JP, Honegger J, Fahlbush R, Trainer PJ, Chew SL, Besser GM, Grossman AB: Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors. J Clin Endocrinol Metab 1998;83:3624–3630.
7.
Otsuka F, Tamiya T, Yamauchi T, Ogura T, Ohmoto T, Makino H: Quantitative analysis of growth-related factors in human pituitary adenomas: Lowered mRNA expression of IGF-I and its receptor in GH-producing adenomas. Regul Pept 1999;83:31–38.
8.
Le Riche V, Asa SL, Ezzat S: Epidermal growth factor and its receptor (EGF-R) in human pituitary adenomas: EGF-R correlates with tumor aggressiveness. J Clin Endocrinol Metab 1996;81:656–662.
9.
Asa SL, Ezzat S: The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev 1998;19:798–827.
10.
Yokoyama S, Thapar K, Kovacs K, Stefaneanu L: Localization of insulin-like growth factor-II mRNA in human pituitary adenomas. Virchows Arch 1998;432:241–246.
11.
Daughaday W: The possible autocrine/paracrine and endocrine roles of insulin-like growth factors of human tumors. Endocrinology 1990;127:1–4.
12.
Bravo R: Synthesis of the nucelar protein cyclin (PCNA) and its relationship with DNA replication. Exp Cell Res 1986;163:287–293.
13.
Zuber M, Tan EM, Ryoji M: Involvement of proliferating cell nuclear antigen (cyclin) in DNA replication in living cells. Mol Cell Biol 1989;9:57–66.
14.
Hsu DW, Hakim F, Biller BMK, De la Monte S, Zerxas NT, Klibanski A, Heldey-Whyte ET: Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence. J Neurosurg 1993;78:753–761.
15.
Bertholon-Grégoire M, Trouillas J, Guigard MP, Loras B, Tourniaire J: Mono- and plurihormonal thyrotropic pituitary adenomas: Pathological, hormonal and clinical studies in 12 patients. Eur J Endocrinol 1999;140:519–527.
16.
Knosp E, Kitz K, Perneczky A: Proliferation activity in pituitary adenomas: Measurement by monoclonal antibody Ki-67. Neurosurgery 1989;25:927–930.
17.
Zervas NT, Swearingen B, Sleeper M, Klibanski A: Biochemical assessment of Cushing’s disease in patients with corticotroph macroadenomas. J Clin Endocrinol Metab 1998;83:1619–1623.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.